PHIO PHARMACEUTICALS CORP. Cash and Restricted Cash
PHIO PHARMACEUTICALS CORP. (PHIO) had Cash and Restricted Cash of $10.78 million as of 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2025-08-14
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.78M.
- 2025-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.28M.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.38M.
- 2024-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2025-06-30 | $10.78M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $13.28M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $5.38M 10-Q · filed 2025-08-14 |
| 2024-09-30 | $5.39M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $4.70M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $6.47M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $8.49M 10-Q · filed 2025-08-14 |
| 2023-09-30 | $8.46M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $11.36M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $9.09M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $11.83M 10-K · filed 2025-03-31 |
| 2022-09-30 | $14.53M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $18.07M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $20.51M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $24.11M 10-K · filed 2024-04-01 |
| 2021-09-30 | $26.58M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $29.48M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $32.74M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $14.29M 10-K · filed 2023-03-22 |
| 2020-09-30 | $16.92M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $18.91M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $13.33M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $6.98M 10-K · filed 2022-03-22 |
| 2019-09-30 | $8.76M 10-Q · filed 2020-11-10 |
| 2019-06-30 | $10.87M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $12.80M 10-Q · filed 2020-05-12 |
| 2018-12-31 | $14.93M 10-K · filed 2021-03-25 |
| 2018-09-30 | $3.29M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $5.37M 10-Q · filed 2019-08-12 |
| 2018-03-31 | $2.66M 10-Q · filed 2019-05-14 |
| 2017-12-31 | $3.63M 10-K · filed 2020-03-26 |
| 2017-09-30 | $5.47M 10-Q · filed 2018-11-14 |
| 2017-06-30 | $7.75M 10-Q · filed 2018-08-14 |
| 2017-03-31 | $10.26M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $12.96M 10-K · filed 2019-03-27 |
| 2015-12-31 | $5.17M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |